The effect of PD-L1/PD-1 immunotherapy in the treatment of squamous non-small-cell lung cancer: a meta-analysis of randomized controlled clinical trials.
Conclusions: Our study proves that PD-L1/PD-1 immunotherapy can significantly improve OS, PFS, ORR, DCR, and 1-y PFS of metastatic squamous NSCLC patients compared with chemotherapy.
PMID: 31903233 [PubMed]
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Conferences | Databases & Libraries | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Respiratory Medicine | Science | Study